Misplaced Pages

Alkermes plc

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Alkermes (company)) Irish-domiciled healthcare company
Alkermes plc
Company typePublic
Traded as
IndustryBiotechnology
Founded1987; 37 years ago (1987)
FounderMichael Wall
HeadquartersDublin, Ireland
Key peopleRichard Pops (CEO)
RevenueIncrease US$1.1 billion (2022)
Operating incomeDecrease US$-20.5 million
Net incomeDecrease US$-158 million (2022)
Total assetsIncrease US$1.9 billion
Total equityIncrease US$1 billion
Number of employees2,100
Websitewww.alkermes.com

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

Products

Alkermes has four proprietary commercial drug products approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, ALKS 2680. ALKS 2680 is in development for the treatment of narcolepsy.

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.

In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo Nordisk.

References

  1. ^ Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.
  2. "Alkermes PLC".
  3. "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.
  4. "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.
  5. "Alkermes, Inc. Company Information". Drugs.com. Retrieved 2023-11-22.
  6. "U.S. Third-Party Medicines | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  7. "Alkermes EU Pharmaceutical Manufacturing Products | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  8. "Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings". Neurology live. 2023-11-06. Retrieved 2023-11-22.
  9. "Alkermes separates cancer drug business as new company Mural". BioPharma Dive. Retrieved 2023-11-22.
  10. "Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk". alkermes.com. 2024-05-02. Retrieved 2024-06-24.

External links

Pharmaceutical companies of the United States
Current
Former
Tax inversion
Other
Categories: